Relapsing-Remitting Multiple Sclerosis Clinical Trial
— TolDecCOMBINEMOfficial title:
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | June 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age between 18-65 years old. 2. Patients diagnosed with RRMS according to 2017 McDonald criteria. 3. MS disease duration < 10 years. 4. Expanded disability status scale (EDSS) from 0 to < 5.5. 5. Patients eligible to start or already are in on treatment with first line immunomodulatory treatment (interferon beta 1a, interferon beta 1b, glatiramer acetate, teriflunomide or dymethyl-fumarate). 6. Able to sign informed consent. 7. Women of child-bearing potential must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence. Exclusion Criteria: 1. Presence of a relapse or use of steroids 30 days prior to screening visit. 2. Concomitant use of any type of immunomodulatory / immunosuppressive therapy. 3. Use of previous immunosuppressive or cytotoxic therapy in the last 6 months. Use of previous alemtuzumab, cladribine or bone marrow or stem cell transplant at any time. 4. Patients unable or unwilling to undergo MRI scans. 5. Severe systemic diseases or history of cancer or hereditary familiar cancer. 6. Clinically relevant concomitant disease: cardiac, gastrointestinal, hepatic, pulmonary, neurological, renal or other major disease. 7. Impossibility to proceed to the leukapheresis (e.g. absence of peripheral venous access). 8. Pregnant or breastfeeding women. 9. Drug or alcohol abuse. 10. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to test positive for HIV antibody at screening. 11. Ongoing known bacterial, viral or fungal infection (with the exception of onychomycosis and dermatomycosis), positive hepatitis B surface antigen or hepatitis C antibody tests at screening. 12. Patients with a known history of syphilis or tuberculosis or test positive for syphilis (positive rapid plasma reagin, RPR) or tuberculosis (positive skin test) at screening. Active or latent tuberculosis (TB). 13. Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity that may interfere with the compliance to the protocol. 14. Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study. 15. Participation in other experimental studies within the previous 90 days prior to screening visit. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínic de Barcelona | Barcelona | |
Spain | Hospital de Sant Pau | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Moisés Broggi | Hospitalet de Llobregat | Barcelona |
Spain | Hospital Universitari de Bellvitge | Hospitalet de Llobregat | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Judit Pich |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes from baseline in the number of CUA lesion (mean number of the sum at week 12, 18 and 24). | week 12, 18 and 24 | ||
Primary | Proportion of patients with any Grade 3 -4 adverse events related to product administration during the study period. | week 24 | ||
Primary | Proportion of patients with any Grade 3 -4 adverse events related to study product. | week 24 | ||
Secondary | Proportion of patients with any Grade 3 -4 adverse events related to study product. | week 24 | ||
Secondary | Proportion of patients with any SAE events related to study product. | week 24 | ||
Secondary | Proportion of patients with at least one MS relapse during the study period. | week 24 | ||
Secondary | Total number of MS relapse at 24 weeks. | week 24 | ||
Secondary | Time to first MS relapse during the study period. | week 24 | ||
Secondary | Changes from baseline in the disability progression by Expanded Disability Status Scale (EDSS) at week 24. | week 24 | ||
Secondary | Changes from baseline in the disability progression by Multiple Sclerosis Functional Composite (MSFC) at week 24. | week 24 | ||
Secondary | Changes from baseline in the number of CUA lesion at week 24. | week 24 | ||
Secondary | Proportion of patients free from CUA lesion, gadolinium-enhancing lesions on T1 MRI and new or enlarged lesions on T2-MRI thought the 24 weeks of study. | week 24 | ||
Secondary | Changes from baseline in the number of Gd-enhancing T1 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24. | week 24 | ||
Secondary | Changes from baseline in number of new or enlarging T2 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24. | week 24 | ||
Secondary | Changes from baseline in brain global, white and gray matter volume and cervical cord volume on MRI at 24 weeks. | week 24 | ||
Secondary | Changes from baseline in the number of cortical lesions on MRI at 24 weeks. | week 24 | ||
Secondary | Changes from baseline in MR measurements of diffuse damage of brain tissue by MTR at 24 weeks | week 24 | ||
Secondary | Changes from baseline in MR measurements of relaxation times of T1 and T2 by MTR at 24 weeks. | week 24 | ||
Secondary | Changes in DTI measures as mean diffusivity (MD), fractional anisotropy (FA), radial diffusivity (Dr) and axial diffusivity (Da) at 24 weeks. | week 24 | ||
Secondary | Changes from baseline in cytokine production (including IFNgamma, IL-17, IL-4 and IL-10) in response to specific peptide stimulation in peripheral blood mononuclear cells (PBMCs) culture supernatants at 12 and 24 weeks. | week 24 | ||
Secondary | Changes from baseline in T cell proliferation to immunogenic peptides at 12 and 24 weeks. | week 24 | ||
Secondary | Changes from baseline in immune cell subsets in PBMCs including PBMC subtypes, T lymphocytes subpopulations and Treg subsets, CD4 and CD8 GM-CSF 'encephalitogenic' T cells and T cell subtypes by activation memory phenotype at 12 and 24 weeks. | week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|